The idea of using sound waves to destroy tissue deep inside the body without a single incision sounds like science fiction. Yet high-intensity focused ultrasound (HIFU) is increasingly the standard of care for specific conditions — and the frontier of active investigation for many more. In 2026, focused ultrasound is FDA-approved for essential tremor, Parkinson's tremor-dominant disease, uterine fibroids, and prostate cancer — and clinical trials are underway in glioblastoma, obsessive-compulsive disorder, Alzheimer's disease drug delivery, and chronic pain. This is a technology whose moment has arrived.
How Focused Ultrasound Works
A focused ultrasound system uses an array of hundreds of ultrasound transducers arranged in a hemisphere. Each transducer emits a low-intensity beam that passes harmlessly through intervening tissue — bone, muscle, and brain — but converges at a focal point where the combined energy generates heat of 55–60°C for 20 seconds, creating a precise lesion of 3–5mm diameter. MRI provides real-time thermometry during treatment, allowing millimeter-precise targeting and temperature monitoring to ensure efficacy without collateral damage.
The result is neurosurgical precision without anesthesia, without incision, without skull opening, and without recovery time. Patients are awake during the procedure, providing real-time feedback that guides targeting.
Essential Tremor: The Established Indication
Essential tremor is the most common movement disorder, affecting 7 million Americans. The FDA-approved target is the ventral intermediate nucleus (VIM) of the thalamus — the same target as deep brain stimulation (DBS) surgery. Focused ultrasound creates a thermal lesion in the VIM, disrupting the tremor circuit. The INSIGHTEC ExAblate Neuro system, FDA-approved for essential tremor since 2016, has now treated over 60,000 patients globally.
The BEST-FUS trial, published in NEJM in 2023, confirmed 5-year durability: 70% of patients maintained ≥50% tremor reduction at 5 years. Adverse events are primarily transient paresthesias (35%) and gait disturbance (15%), which resolve within weeks to months.
Parkinson's Tremor: The 2023 Expansion
FDA expanded the essential tremor approval to tremor-dominant Parkinson's disease in 2023, targeting either the VIM or the subthalamic nucleus (STN). Two-year data shows 63% improvement in tremor-dominant Parkinson's symptom scores, with good durability. The primary limitation is that focused ultrasound treats tremor specifically — not the bradykinesia and rigidity that dominate many Parkinson's phenotypes.
The Frontier: Opening the Blood-Brain Barrier
Perhaps the most transformative application in development is using low-intensity focused ultrasound to transiently open the blood-brain barrier (BBB) — the endothelial tight junctions that prevent most drugs from entering the brain. By injecting microbubbles (microscopic gas-filled spheres) intravenously and then applying low-intensity focused ultrasound, researchers can transiently open the BBB at the focal point for 6–8 hours, allowing drugs that would normally be excluded to penetrate the brain at therapeutic concentrations.
Applications under investigation:
- Glioblastoma: Delivering chemotherapy (temozolomide, carboplatin) directly into tumor tissue. Phase II trial at Sunnybrook Health Sciences Centre showed 4.5-fold increase in drug concentration at the treatment zone vs untreated brain.
- Alzheimer's disease: Enhancing delivery of amyloid-clearing antibodies (lecanemab, donanemab) to plaque-rich regions. Phase I safety trial underway.
- OCD and depression: BBB opening in the anterior limb of the internal capsule to enhance local drug delivery.
Uterine Fibroids: The Most-Used Indication
The FDA cleared focused ultrasound for symptomatic uterine fibroids in 2004. It remains the only non-invasive, uterus-preserving treatment for fibroids, relevant for women who wish to avoid hysterectomy or myomectomy. Real-world outcomes show 70–80% symptom reduction at 12 months, with approximately 20% of patients requiring re-treatment at 3 years.
Conclusion
Focused ultrasound is not a single technology but a platform capable of thermal ablation, mechanical disruption, neuromodulation, and drug delivery enhancement — each mediated by different parameters of the same fundamental physics. As the range of targets and applications expands through ongoing trials, this incisionless surgical tool is positioned to become one of the defining medical technologies of the next decade. Healthcare facilities can find relevant surgical supplies in our catalog.
